SCHEMBL3058290

SCHEMBL3058290

COc1cc([N+](=O)[O-])ccc1-c1ccc(C=NNc2nc3nonc3nc2Nc2ccc(Cl)cc2)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 14/20 0.54
KMT2A Q03164 14/20 0.54
MAPT P10636 9/20 0.54
CRHBP P24387 3/20 0.51
CRHR2 Q13324 3/20 0.51
POLB P06746 4/20 0.51
TDP1 Q9NUW8 2/20 0.51
MCL1 Q07820 3/20 0.49
ALDH1A1 P00352 4/20 0.44
RAB9A P51151 3/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.41
PKM P14618 1/20 0.40
DUSP3 P51452 1/20 0.40
BLM P54132 1/20 0.40
PTPN5 P54829 1/20 0.40
PTPN11 Q06124 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
BIRC5 O15392 1/20 0.40
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3058288 1.00 MEN1 (0.54) MEN1KMT2AMAPTCRHBPCRHR2
SCHEMBL6414075 0.83 MAPT (0.53) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL6414077 0.83 MAPT (0.53) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL3050786 0.82 MEN1 (0.51) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL6415669 0.76 KMT2A (0.53) MEN1KMT2AMAPTCRHBPCRHR2
SCHEMBL6415667 0.76 KMT2A (0.53) MEN1KMT2AMAPTCRHBPCRHR2
SCHEMBL6438176 0.76 MAPT (0.51) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL6438174 0.76 MAPT (0.51) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL3045614 0.76 MEN1 (0.52) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL6436712 0.76 MAPT (0.57) MEN1KMT2AMAPTPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US claimed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US claimed
EP-1799689-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-06-27 EP claimed
WO-2006044402-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US disclosed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, VHL, RB1 MEN1 35/4885KMT2A 3960/4885MAPT 3908/4885
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, RB1, CA5A MEN1 37/4885KMT2A 4211/4885MAPT 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.